We have demonstrated pre-clinically and more recently clinically, that by combining Ipilimumab (an anti-CTLA4 antibody) , a currently approved treatment for metastatic melanoma, with our intratumoral tilsotolimod (IMO-2125), we can enable these therapies to have deeper and longer-lasting responses in patients who are refractory to anti-PD1 therapy.
We are currently enrolling our Phase 2 multi-center clinical trial of tilsotolimod in combination with Ipilimumab in PD-1 refractory metastatic melanoma patients. We also are enrolling an arm in this trial to test the combination of tilsotolimod with Pemrolizumab and have recently initiated a multi-center clinical trial of IMO-2125 as a monotherapy in melanoma and numerous other solid tumors and plan to open additional trials to explore further combination regimens in other solid tumor types.
Based on the data we have generated to date, we are also in parallel enrolling a global Phase 3 clinical trial in anti-PD-1 refractory patients measuring the combination of tilsotolimid and ipilimumab versus ipilimubab treatment along. This trial will be enrolling approximately 300 patients across 80 global trial sites.